Ovarian Cancer 2022
DOI: 10.1136/ijgc-2022-esgo.597
|View full text |Cite
|
Sign up to set email alerts
|

2022-RA-937-ESGO Rucaparib MAintenance after bevacizumab maintenance following carboplatin based chemotherapy in primary ovarian cancer

Abstract: among which activation of DNA replication and changes in cell cycle regulation were notable. Organoids which retained regeneration capacity after carboplatin exposure, showed a sustained shift in expression of stemness associated surface marker CD133+ in the subsequent passages as showed by fluorescence-activated cell sorting and Western blot Conclusion We hereby propose OFE assay as a novel functional readout for carboplatin sensitivity. Furthermore, expression profile changes in organoids during acute respon… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles